Hold the phone, biopharma: FDA-imposed clinical holds are on the rise
Are clinical holds on the rise? According to one analysis, signs point to yes, and one field, in particular, is proving a likely culprit.
Jefferies’ Michael Yee came out with a note Sunday detailing the sharp rise of FDA-imposed holds over the last 18 to 24 months following a decade of relatively little movement on that trend. And if things continue unabated, 2022 has the potential to eclipse even last year’s mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.